Exploratory Study of Inhaled Afatinib Dimaleate PK Profile

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

December 25, 2025

Study Completion Date

March 25, 2026

Conditions
Lung CancerOral CancerMelanoma
Interventions
DRUG

Afatinib Dimaleat

printed capsule containing 40 mg afatinib dimaleate

BIOLOGICAL

inhalation of afatinib dimaleate

inhalation stable form of afatinib dimaleate at an equivalent therapeutic dose in a single-use maintenance-free ultrasonic inhaler with controlled frequency and number of inhalations

Trial Locations (1)

Unknown

Central Contact, Auckland

All Listed Sponsors
lead

Petrov, Andrey

OTHER